ReviewFrontiers in immunology2025
Case report and literature review: tislelizumab combined with lenvatinib and polymeric micellar paclitaxel for thymic squamous cell carcinoma.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymic squamous cell carcinoma (TSCC) is a rare malignancy with an annual incidence of 0.15-0.32 per 100,000 population and exhibits aggressive behavior including early metastasis. Anti-PD-1 immunotherapy combined with chemotherapy has emerged as a potential strategy for TSCC. We report a 60-year-old male with a 1-month history of persistent dry cough and generalized fatigue. Diagnostic evaluation revealed advanced TSCC (cT3N2M1b), with bilateral lung, right pleural, left adrenal, mediastinal and right hilar lymph nodes metastases. Significantly elevated CA125 and CYFRA211 levels were observed. Initial first-line carboplatin plus polymeric micellar paclitaxel (PM-PTX) stabilized the disease. Subsequent adjustments to the immunotherapy regimen led to a two-phase approach combining tislelizumab, lenvatinib, PM-PTX, with or without carboplatin. This strategy achieved sustained tumor burden reduction with improved quality of life and nutritional status throughout treatment, without significant immune-related adverse events (irAEs). Additionally, we discuss the mechanisms of combination therapy, immunotherapy toxicities in thymic malignancies, and propose personalized combination strategies to guide clinicians in selecting treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.